- Home
- NVS
NVS
Novartis AG
as of 08-25-2026 3:59pm EST
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
| Founded: | 1895 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 293.9B | IPO Year: | 2001 |
| Target Price: | $144.00 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | Dividend Payout Frequency: | N/A | |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $121.57 - $170.46 | Next Earning Date: | 04-28-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 2.3% | Revenue Growth (next year): | 5.27% |
| P/E Ratio: | 23.13 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | -0.40% |
Compare NVS vs Leading Stocks
See how NVS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NVS Novartis AG - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.